The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: Importance of mRNA half-life regulation

International Journal of Cancer

Volumn 114, Issue 4, 2005, Pages 598-605

  Vockerodt, Martina ^a,b   Pinkert, Diana ^a   Smola Hess, Sigrun ^b   Michels, Astrid ^b   Ransohoff, Richard M ^c   Tesch, Hans ^b   Kube, Dieter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

EBV LMP1; IP 10; mRNA stability

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN;

ARTICLE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; ENZYME INHIBITION; GENE CONTROL; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOMA CELL; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY MECHANISM; RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

AMINO ACID MOTIFS; ANTIGENS, CD40; BLOTTING, WESTERN; CELL LINE, TUMOR; DACTINOMYCIN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INTERFERON TYPE II; INTERLEUKIN-18; LYMPHOMA; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RECEPTORS, CHEMOKINE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; VIRAL MATRIX PROTEINS;

EID: 14844312896     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20759     Document Type: Article

References (42)

1. Rickinson AB, Kieff E. Epstein Barr Virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996. 2397-446.
2. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-4.
3. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, RaabTraub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963-8.
4. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001;11:435-44.
5. Brennan P. Signalling events regulating lymphoid growth and survival. Semin Cancer Biol 2001;11:415-21.
6. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131-40.
7. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor- kappaB, and stress-activated protein kinase. J Immunol 1998;160:1116-21.
8. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam M, Reed JC, Kieff E, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-54.
9. Mosialos G, Birkenbach M, Yalamanchili R, Van AT, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
10. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996;16:7098-108.
11. Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 1999;19:5759-67.
12. Eliopoulos AG, Blake S, Floettmann JE, Rowe M, Young LS. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 1999;73:1023-35.
13. Huen DS, Henderson SA, Croom CD, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
14. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997;16:6478-85.
15. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M, Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 1999;18:3064-73.
16. Izumi KM, Cahir McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J Virol 1999;73:9908-16.
17. Vockerodt M, Tesch H, Kube D. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway. Genes Immun 2001;2:433-41.
18. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M. Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 2001;276:1195-203.
19. Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 1993;177:295-304.
20. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D. The Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) induces Interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001;2:183-98.
21. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996;87:2918-29.
22. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274: 16085-96.
23. Setsuda J, Teruya-Feldstein J, Harris NL, Ferry JA, Sorbara L, Gupta G, Jaffe ES, Tosato G. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol 1999;155:257-65.
24. Maggio EM, Van Den Berg A, Visser L, Diepstra A, Kluiver J, Emmens R, Poppema S. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002;99:665-72.
25. Altenburg A, Baldus SE, Smola H, Pfister H, Hess S. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999;162:4140-7.
26. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol 1998;161:4736-44.
27. Kube D, Vockerodt M. Transient gene expression and MACS enrichment. In: Wilson J, ed. Epstein Barr Virus protocols in methods in molecular biology, vol. 174. Totowa, NJ: Humana, 2001. 155-63.
28. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997;14:2899-916.
29. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 1997;15:1851-8.
30. Mitchell T, Sudgen B. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of EBV. J Virol 1995;69:2968-72.
31. Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, Di Battista JA. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001;276:31720-31.
32. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS, Williams BR. p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 2003;23:425-36.
33. Bakheet T, Williams BR, Khabar KS. ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res 2003;31:421-3.
34. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 1999;19:6742-53.
35. Huang ZF, Massey JB, Via DP. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol 2000;59:187-94.
36. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999;274:264-9.
37. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001;98:6905-10.
38. Floettmann JE, Eliopoulos AG, Jones M, Young LS, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene 1998;17:2383-92.
39. Schultheiss U, Puschner S, Kremmer E, Mak TW, Engelmann H, Hammerschmidt W, Kieser A. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. Embo J 2001;20:5678-91.
40. Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J, Nakano H, Mak TW, Yeh WC, Li X, Akira S, Suzuki N, et al. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci USA 2003;100:15595-600.
41. Klein SC, Jucker M, Abts H, Tesch H. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV. Hematol Oncol 1995;13:121-30.
42. Klein SC, Kube D, Abts H, Diehl V, Tesch H. Promotion of IL8, IL10, TNFalpha and TNFbeta production by EBV infection. Leukemia Res 1996;20:633-6.